Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Account Payables (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Change in Account Payables over the past 3 years, most recently at -$738000.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at -$738000.0 for Q4 2025, down 227.02% from a year ago — trailing twelve months through Dec 2025 was $3.0 million (up 222.98% YoY), and the annual figure for FY2025 was $3.0 million, up 222.98%.
  • Change in Account Payables for Q4 2025 was -$738000.0 at Tonix Pharmaceuticals Holding, down from $1.0 million in the prior quarter.
  • Over the last five years, Change in Account Payables for TNXP hit a ceiling of $3.7 million in Q2 2024 and a floor of -$6.4 million in Q3 2024.
  • Median Change in Account Payables over the past 3 years was $578000.0 (2023), compared with a mean of $35916.7.
  • Peak annual rise in Change in Account Payables hit 425.22% in 2024, while the deepest fall reached 725.07% in 2024.
  • Tonix Pharmaceuticals Holding's Change in Account Payables stood at -$3.9 million in 2023, then surged by 114.76% to $581000.0 in 2024, then crashed by 227.02% to -$738000.0 in 2025.
  • The last three reported values for Change in Account Payables were -$738000.0 (Q4 2025), $1.0 million (Q3 2025), and $3.1 million (Q2 2025) per Business Quant data.